Pharmaceutical

BlueRock and bit.bio link to develop regulatory T cell-based therapies

BlueRock Therapeutics signed an agreement with bit.bio to discover and manufacture iPSC-derived regulatory T cells (Tregs) based therapies.

Aug 4, 2023 - 20:00
BlueRock and bit.bio link to develop regulatory T cell-based therapies
BlueRock Therapeutics signed an agreement with bit.bio to discover and manufacture iPSC-derived regulatory T cells (Tregs) based therapies.
Read the original article

Tags:

Previous Article

Bangladesh and the dengue vaccine question

Next Article

The next privacy battle will be fought over health data

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: For brain-computer interfaces, the commercial hurdles may be bigger than scientific ones

STAT+: For brain-computer interfaces, the commercial hu...

Aug 5, 2023

Plocabulin by Pharma Mar for Peritoneal Cancer: Likelih...

Nov 16, 2023

Santa Ana Bio secures $168m for inflammatory disease treatments

Santa Ana Bio secures $168m for inflammatory disease tr...

Jun 16, 2024